Arena Pharma (ARNA) Shares Downgraded at WBB Securities, CRT Capital This Morning
Tweet Send to a Friend
Get Alerts ARNA Hot Sheet
Price: $8.30 +2.98%
Rating Summary:
3 Buy, 8 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
3 Buy, 8 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade ARNA Now!
Analysts are continuing to downgrade shares of the now-battered Arena Pharma (Nasdaq: ARNA) this week. The company's stock tumbled by an astounding 98% last week amid concerning FDA briefing documents and the resulting decision by an FDA panel not to recommend approval of Arena's weight-loss product lorcaserin.
Today, analysts at both WBB Securities and CRT Capital have lowered their investment ratings on shares of Arena Pharma. WBB now rates the stock a Hold, down from Strong Buy while CRT now rates the stock a Fair Value, down form Buy previously. WBB lowered its price target on ARNA shares from $7 to $2.
Shares of Arena Pharma are set to open this morning's session down about 1% to $1.97.
To track all the market-moving upgrades/downgrades on shares of Arena Pharma, visit our Analyst Ratings page.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Today, analysts at both WBB Securities and CRT Capital have lowered their investment ratings on shares of Arena Pharma. WBB now rates the stock a Hold, down from Strong Buy while CRT now rates the stock a Fair Value, down form Buy previously. WBB lowered its price target on ARNA shares from $7 to $2.
Shares of Arena Pharma are set to open this morning's session down about 1% to $1.97.
To track all the market-moving upgrades/downgrades on shares of Arena Pharma, visit our Analyst Ratings page.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- Canaccord Genuity Downgrades Cirrus Logic (CRUS) to Hold
- Argus Downgrades Saks Inc. (SKS) to Hold
Create E-mail Alert Related Categories
Downgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
